Weekly Analysts’ Ratings Changes for uniQure (QURE)

Several brokerages have updated their recommendations and price targets on shares of uniQure (NASDAQ: QURE) in the last few weeks:

• 10/5/2026 – uniQure was downgraded by Barclays PLC from “overweight” to “equal weight”. They now have a $28.00 price target on the stock, down from $60.00.
• 10/2/2026 – uniQure had its price target lowered by Royal Bank Of Canada from $65.00 to $48.00. They now have an “outperform” rating on the stock.
• 9/30/2026 – uniQure had its price target lowered by The Goldman Sachs Group, Inc. from $46.00 to $31.00. They now have a “neutral” rating on the stock.
• 9/29/2026 – uniQure had its “overweight” rating reaffirmed by Wells Fargo & Company. They now have a $75.00 price target on the stock.
• 9/29/2026 – uniQure had its “buy” rating reaffirmed by HC Wainwright.
• 9/23/2026 – uniQure was upgraded by William Blair to “strong-buy”.
• 9/21/2026 – uniQure was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 9/5/2026 – uniQure was downgraded by Wall Street Zen from “hold” to “sell”.
• 9/2/2026 – uniQure is now covered by William Blair. They set an “outperform” rating on the stock.
• 8/15/2026 – uniQure was upgraded by Wall Street Zen from “sell” to “hold”.

uniQure N.V. is a biotechnology company focused on developing gene therapies intended to treat serious and potentially life-threatening diseases. The company uses adeno-associated virus (AAV) delivery technology to introduce genetic material into patients’ cells, with the goal of addressing the underlying causes of disease through a single administration.

uniQure’s lead commercial product, Hemgenix (etranacogene dezaparvovec), is a gene therapy for adults with hemophilia B who use factor IX replacement therapy.